Pregled bibliografske jedinice broj: 944802
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. // Acta clinica Croatica, 57 (2018), 1; 190-215 doi:10.20471/acc.2018.57.01.27 (međunarodna recenzija, članak, stručni)
CROSBI ID: 944802 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Guidelines for Diagnosis and Treatment of Chronic
Lymphocytic Leukemia. Krohem B-Cll 2017.
Autori
Jakšić, Branimir ; Pejša, Vlatko ; Ostojić- Kolonić, Slobodanka ; Kardum-Skelin, Ika ; Bašić- Kinda, Sandra ; Coha, Božena ; Gverić- Krečak, Velka ; Vrhovac, Radovan ; Jakšić, Ozren ; Aurer, Igor ; Sinčić-Petričevi, Jasminka ; Načinović- Duletić, Antica ; Nemet, Damir
Izvornik
Acta clinica Croatica (0353-9466) 57
(2018), 1;
190-215
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
chronic lymphocytic leukemia ; practice guidelines as topic ; precision medicine ; Croatia ; KROHEM
Sažetak
Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B- CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We define current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on new diagnostic stratification and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. This is a rapidly evolving field as a great number of ongoing clinical trials constantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
Opća bolnica "Dr. Josip Benčević",
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb,
Klinički bolnički centar Rijeka,
Sveučilište Libertas
Profili:
Božena Coha
(autor)
Velka Gverić-Krečak
(autor)
Vlatko Pejša
(autor)
Antica Duletić-Načinović
(autor)
Ozren Jakšić
(autor)
Igor Aurer
(autor)
Ika Kardum-Skelin
(autor)
Branimir Jakšić
(autor)
Damir Nemet
(autor)
Radovan Vrhovac
(autor)
Slobodanka Ostojić Kolonić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE